Literature DB >> 7561796

Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS.

A D Gurusinghe1, S A Land, C Birch, C McGavin, D J Hooker, G Tachedjian, R Doherty, N J Deacon.   

Abstract

Sequential human immunodeficiency virus type 1 (HIV-1) isolates were obtained over a 29-month period from a person before, during, and after AZT therapy. DNA sequence analysis of polymerase chain-amplified reverse-transcriptase gene showed a gradual accumulation of mutations to peak resistance (IC50 2.13 microM AZT) in association with mutations at codons 44, 210, and 369, as well as at 41, 67, 70, and 215. Eight months after cessation of AZT therapy, when an HIV-1 isolate from the patient was again sensitive to AZT, these mutations had all returned to the pretherapy sequence.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7561796     DOI： 10.1002/jmv.1890460312

Source DB:  PubMed          Journal:  J Med Virol        ISSN： 0146-6615            Impact factor:   2.327


  7 in total

1.  Sequence analysis of the polymerase domain of HIV-1 reverse transcriptase in naive and zidovudine-treated individuals reveals a higher polymorphism in alpha-helices as compared with beta-strands.

Authors:  L Medrano; L Menéndez-Arias; R De Jorge; M L Villahermosa; G Contreras; L Pérez-Alvarez; A Moya; R Nájera
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

2.  Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.

Authors:  P R Harrigan; S Bloor; B A Larder
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.

Authors:  D J Hooker; G Tachedjian; A E Solomon; A D Gurusinghe; S Land; C Birch; J L Anderson; B M Roy; E Arnold; N J Deacon
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Convergent evolution of reverse transcriptase (RT) genes of human immunodeficiency virus type 1 subtypes E and B following nucleoside analogue RT inhibitor therapies.

Authors:  H Sato; Y Tomita; K Shibamura; T Shiino; T Miyakuni; Y Takebe
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

Authors:  T Imamichi; S C Berg; H Imamichi; J C Lopez; J A Metcalf; J Falloon; H C Lane
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.

Authors:  G Tachedjian; J Mellors; H Bazmi; C Birch; J Mills
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

7.  Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses.

Authors:  A D Kelleher; C Long; E C Holmes; R L Allen; J Wilson; C Conlon; C Workman; S Shaunak; K Olson; P Goulder; C Brander; G Ogg; J S Sullivan; W Dyer; I Jones; A J McMichael; S Rowland-Jones; R E Phillips
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.